Please assess the completion status of the following clinical trial:

Trial Title: BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven advanced melanoma.~* Anti-PD-1 monotherapy of advanced (unresectable or metastatic) melanoma (prescribed within its approved indication as per usual practice according to RIZIV/INAMI regulations) in the first-line setting.~* No prior systemic therapy for advanced melanoma.~* Have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.~* At least 18 years of age.~Exclusion Criteria:~* Prior treatment with any drug specifically targeting T-cell co-stimulation or immune checkpoints (e.g., antibodies targeting PD-(L)1 or CTLA-4, chimeric antigen receptor T (CAR-T) cell therapy).~* Metastasis-directed therapy (surgery or radiotherapy) with definitive intent (local therapy to address symptomatic sites of disease is permitted).~* Previous systemic treatment for advanced melanoma.~* Active central nervous system (CNS) metastases (previously treated brain metastases are permitted if stable) or carcinomatous meningitis.~* Diagnosis of any other malignancy within 5 years prior to study inclusion, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast or of the cervix, low-risk prostate cancer on surveillance without any plans for treatment intervention, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease and symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with advanced melanoma (Type: None): Patients receiving anti-PD-1 monotherapy (Nivolumab or Pembrolizumab) in the first-line setting

Based on this trial design, predict the completion outcome and termination type (if applicable).